NCT03283696 2020-09-10A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue SarcomaEli Lilly and CompanyPhase 1 Completed24 enrolled 21 charts
NCT02326025 2019-11-21A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue SarcomaEli Lilly and CompanyPhase 1 Completed49 enrolled 17 charts
NCT02783599 2019-08-12A Study of Olaratumab (LY3012207) in Participants With Soft Tissue SarcomaEli Lilly and CompanyPhase 1 Completed51 enrolled 22 charts